Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus
| Autor: | Oguz, Ayten, Sahin, Murat, Tuzun, Dilek, Kurutas, Ergul B., Ulgen, Cansu, Bozkus, Ozlem, Gul, Kamile |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Glycated Hemoglobin
Male body composition obesity Sarcopenia Observational Study Middle Aged Myostatin Physical Functional Performance myokine Body Mass Index Fibronectins Walking Speed Cross-Sectional Studies Diabetes Mellitus Type 2 Predictive Value of Tests Risk Factors Prevalence Humans Female type 2 diabetes Muscle Strength Obesity Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | We aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO. Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients. The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|